The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

Some cats wobble, fall over constantly, and generally have no control over their movements. These cats live with the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to Reata Pharmaceuticals Inc.’s new drug application for omaveloxolone to ...

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

European Commission approves OMP Designation for NLX-112 (befiradol) following compelling results in studies funded by the US Dept of Defense. This OMP designation is a milestone for Neurolixis as we ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.

A key opinion leader outlines common adverse events associated with omaveloxolone treatment in Friedreich's ataxia patients and describes strategies used to manage or minimize these adverse effects.

Medical experts use the term “cerebellar ataxia” when referring to conditions that lead to a lack of muscle control. Dysmetria is one form of cerebellar ataxia. Dysmetria occurs due to the improper ...

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage ...

AJMC ®: What is your background in treating Friedreich ataxia (FA) in clinical practice and in clinical trials? KUO: I am the director of Columbia University’s ataxia center and have extensive ...

Monthly infusions of an investigational product that encapsulates dexamethasone sodium phosphate into autologous erythrocytes (EryDex) appeared safe but did not significantly improve neurological ...